Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsightUnusual Whales·Aug 18 at 09:57 AM4506
Sumitomo treats first patient in Phase I/IIa trial of DSP-3077WorldPharmaceuticals·Aug 13 at 04:49 AM4506
Sumitomo Pharma rejects Gotham City Research report on AMCHEPRY, Sumitomo Chemical saysPUBT·Aug 11 at 06:33 PM4506
Sumitomo Pharma (TSE:4506) Reports Strong First Quarter Earnings, Is The Discount Too Deep?Simplywall·Aug 10 at 02:35 PM4506
Sumitomo Pharma disputes Gotham City Research report, says claims “clearly inconsistent” with factsPUBT·Aug 6 at 11:10 PM4506
Sumitomo Pharma says no evidence of misstatements after Gotham City Research reportPUBT·Aug 4 at 12:53 AM4506
Sumitomo Pharma names Katsunori Maruta head of program management at Sumitomo Pharma AmericaPUBT·Aug 2 at 08:06 PM4506
Sumitomo Pharma Q1 FY27 net profit rises 51.7% to JPY 17 billion; revenue increases 19.9% to JPY 129.5 billionPUBT·Jul 31 at 01:36 AM4506
